Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?

Area of Science:

• Neurotechnology
• Bioethics
• Regulatory Science

Background:

• Rapid development of implantable brain-computer interfaces (BCIs) presents dual-use potential for therapy and human enhancement.
• The distinction between therapeutic and enhancement applications of BCIs is currently ill-defined.
• Existing regulatory frameworks, like the FDA's safe-and-effective standard, may be insufficient for BCIs spanning therapy to enhancement.

Purpose of the Study:

• To argue that the US Food and Drug Administration (FDA) should not be responsible for regulating brain-computer interfaces (BCIs).
• To assert that the FDA's mandate is inadequate for evaluating the societal benefits and value-laden aspects of BCIs.
• To propose that regulatory oversight for BCIs should be reconsidered due to their complex ethical and societal implications.

Main Methods:

• This article presents a critical analysis of the FDA's current regulatory approach.
• It examines the limitations of the "safe-and-effective" standard in the context of neurotechnology.
• The study employs ethical and societal value considerations to critique existing regulatory paradigms.

Main Results:

• The FDA's "safe-and-effective" standard is ill-equipped to handle the subjective, value-laden assessments required for BCI approval.
• Determining the societal benefits of BCIs necessitates ethical deliberations beyond the FDA's scope and expertise.
• The current regulatory framework is inadequate for devices with both therapeutic and enhancement capabilities.

Conclusions:

• BCI regulation should not be overseen by the FDA due to the inadequacy of its current standards.
• A new regulatory approach is needed that can address the complex ethical and societal implications of BCIs.
• Specialized bodies or revised frameworks are required to evaluate the benefits and risks of neurotechnologies for therapy and enhancement.